Versant Venture Capital VII, L.P. 3
3 · LENZ Therapeutics, Inc. · Filed Mar 25, 2024
Insider Transaction Report
Form 3
Versant Venture Capital VII, L.P.
10% Owner
Holdings
Warrant (Right to Buy)
Exercise: $10.64From: 2024-03-21Exp: 2027-10-30→ Common Stock (70,534 underlying)- 1,598,789
Common Stock
Footnotes (2)
- [F1]These securities were acquired pursuant to that certain Agreement and Plan of Merger by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), and Lenz Therapeutics, Inc., a Delaware corporation ("LENZ"), pursuant to which the Merger Sub merged with and into LENZ (the "Merger"), with LENZ continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the Merger.
- [F2]These securities are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII disclaims beneficial ownership of the shares held by VVC VII, except to the extent of their respective pecuniary interests therein.